Bannerbild German Brest Group - Forschung

Research projects conducted by the German Breast Group

The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.

With the help of additional scientific research projects, we strive to gain further insights into this disease.

Research News

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

  • 28.02.2018 Paper of the month: February 2018

    The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd